title: The changing world of drug development.
abstract: Cancer drug development is undergoing a substantial shift nowadays. The underlying drivers are multi-factorial. On the one side, drug development is performed more rationally than ever, profiting from the scientific advances in molecular biology in general and the elucidation of the various "omes" from genome to metabolome in particular. On the other side, it is based on enormous technological progress, e.g., in the field of genome sequencing, and in that of adequate handling of the resulting plethora of data. The high attrition rate of oncologic drugs under development in the past and the pressure from the side of the payers make it necessary to find permanently new answers for and adaptations of the process of drug development. In this context, it is necessary to respect arguments and views from the various perspectives of all the relevant stakeholders. Together with a group of international experts from different perspectives of drug development, this special issue will illustrate the respective role of patients, laboratory, clinical trials, drug companies, regulatory bodies, and also the economic principle in drug development, aiming at facilitating drug research in the near future.
authors.affiliation: Ludwig Boltzmann Institute for Applied Cancer Research-LB Cluster Translational Oncology, Center for Oncology and Hematology, Kaiser Franz Josef-Spital, Vienna, Austria; European Organisation for Research and Treatment of Cancer (EORTC)-New Drug Advisory Committee (NDAC), Brussels, Belgium.
authors.forename: Christian
authors.initials: C
authors.lastname: Dittrich
keywords: Cancer drug development; biomarker; personalized medicin; stratified medicine; translational research